ROCKAWAY, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the third quarter ended September 30, 2022, after the close of the market on Thursday, November 3, 2022. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions.
Thursday, November 3, 2022, 4:30 PM EDT
Domestic: 877-269-7756
International: 201-689-7817
Conference ID: 13733010
Webcast: electroCore Earnings Webcast
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit www.electrocore.com.
Contact:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital
The ‘My Mental Health Journey’ registry is now enrolling U.S.-based adults experiencing symptoms of depression.…
The advanced AI solutions and AI medical scribe will assist the practice in streamlining clinical…
WASHINGTON, DC / ACCESSWIRE / April 4, 2024 / The National Alliance on Mental Illness…
TORONTO, ON / ACCESSWIRE / April 4, 2024 / Closing the Gap Healthcare (CTG) announced…
JACKSON CENTER, PA / ACCESSWIRE / April 4, 2024 / Halberd Corporation's (OTC PINK:HALB) Patented…
The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI's single dose Lassa…